“Exciting time to be in neurology. Treatments here now and coming soon are transforming patient lives.” A modified quote from the plenary session summing up the hope we all have for our patients. #ABNINA23 Association of British Neurologists

We agree with every word of this. Please RT if you do too.

Save the date for MS Frontiers 2024! Our biennial research conference will take place in Liverpool on 4-5 July 2024, bring together scientists, clinicians and health care professionals to network and share the latest advances in MS research. mssoc.uk/472rvzr

Some workshops solidify what you already know. #CoachMS organised by Klaus Schmierer🎗️🇺🇦 and Andrea Stennett PhD has reinforced the value of coaching skills to every interaction with others (patients, colleagues, mentees and loved ones). Thank you so much to Sheba Medical Center for sharing.

It's time to stop dumping thankless tasks on women. Women get more asks than men to serve on committees, plan events, and take notes. They're more likely to be penalized if they say no—and taken for granted if they say yes. Work should be divided equitably by role, not gender.

Too much loyalty can harm workers who risk being given extra work for little extra reward. After all, dogs are known for their loyalty but not for their brains econ.st/4cpf3Nl 👇

The opening plenary highlighting the importance of sleep to brain health. My jet lagged brain agrees. #AANAM I am going to catch the session on jet lag on demand later to learn to manage my symptoms. Anyone have any tips to share

Sometimes an encounter just gives you hope that things will get better in the future. Give hope to others it’s the best gift you can give anyone.

On route to Copenhagen to make most of city and find the best places to eat before #ectrims2024 begins.

Thouvenot: Largest therapeutic trial of vitamin D therapy in #MS. Oral vitamin D 100,000 IU every two weeks reduced disease activity by 34% in CIS patients and in early RRMS. #ECTRIMS2024

Hogenboom (NL): first results of BLOOMS trial: standard vs extended interval dosing of ocrelizumab based on B-cell counts. No difference in efficacy (Relapses and MRI lesions)! (Long term results to follow) Big difference in intervals are seen (see slide) #ECTRIMS2024